Patient blood management (PBM) — a multidisciplinary, evidence-based approach to optimizing patient outcomes by managing and preserving a patient's own blood — has emerged as a quality standard in major surgical programs worldwide following decades of evidence accumulating that allogeneic blood transfusion carries significant risks that were historically underappreciated. The WHO adopted a resolution supporting PBM implementation globally in 2010; The Joint Commission and other accreditation bodies have incorporated blood stewardship metrics into quality reporting. The evidence consistently demonstrates that PBM programs simultaneously reduce transfusion rates by 40–60%, reduce healthcare costs, and improve patient outcomes across metrics including mortality, infection, ICU admission, and hospital length of stay.
The Risks of Allogeneic Transfusion
The benefits of red blood cell (RBC) transfusion for treating symptomatic anemia are unquestionable; the clinical controversy concerns transfusion at higher hemoglobin thresholds where risks may outweigh benefits. Transfusion-related adverse effects include: transfusion-associated circulatory overload (TACO) — the most common serious transfusion complication, affecting 1–6% of hospitalized transfused patients; transfusion-related acute lung injury (TRALI) — a leading cause of transfusion-related mortality; transfusion-transmitted infection (residual risk 1 in 1.5 million for HIV, 1 in 1.2 million for HCV per unit); immunomodulation — allogeneic blood exposure activates immunosuppressive pathways that increase postoperative infection and cancer recurrence in certain contexts. A landmark 2011 JAMA meta-analysis of 272 observational studies found liberal transfusion strategies independently associated with 68% higher mortality and 88% higher pneumonia risk.
The Three Pillars of PBM
Pillar 1 — Optimize red cell mass: Identify and treat preoperative anemia before elective surgery. Preoperative anemia is the strongest independent predictor of transfusion: Hgb <13 g/dL in men and <12 g/dL in women. Treatment based on etiology — iron deficiency (IV iron supplementation achieves >10 g/dL increase in 2–4 weeks), B12/folate deficiency (supplementation), inflammatory anemia (erythropoiesis-stimulating agents with iron in selected patients). Pillar 2 — Minimize blood loss: Surgical hemostasis techniques (meticulous technique, electrocautery, topical hemostatic agents), intraoperative cell salvage (autologous blood recovery/reinfusion — highly effective for cardiac, orthopedic, and major vascular surgery, reducing transfusion by 40–50%), antifibrinolytic agents (tranexamic acid — 30–50% blood loss reduction, now standard of care for TKA/THA and cardiac surgery), and acute normovolemic hemodilution (ANH) in selected cases. Pillar 3 — Harness and optimize anemia tolerance: Evidence-based restrictive transfusion thresholds (transfuse for Hgb <7 g/dL in hemodynamically stable non-cardiac patients — TRICC trial; <8 g/dL in cardiac patients — TRACS trial), supplemental oxygen optimization, and fever management. Surgical facilities committed to PBM programs should maintain comprehensive IV therapy supplies and blood management infrastructure.
